The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation
Abstract
Summary: The revised UKHCDO factor (F) VIII/IX Inhibitor Guidelines (2000) are presented. A schema is proposed for inhibitor surveillance, which varies according to the severity of the haemophilia and the treatment type and regimen used. The methodological and pharmacokinetic approach to inhibitor surveillance in congenital haemophilia has been updated. Factor VIII/IX genotyping of patients is recommended to identify those at increased risk. All patients who develop an inhibitor should be considered for immune tolerance induction (ITI). The decision to attempt ITI for FIX inhibitors must be carefully weighed against the relatively high risk of reactions and the nephrotic syndrome and the relatively low response rate observed in this group. The start of ITI should be deferred until the inhibitor has declined below 10 Bethesda Units/ml, where possible. ITI should continue, even in resistant patients, where it is well tolerated and so long as there is a convincing downward trend in the inhibitor titre. The choice of treatment for bleeding in inhibitor patients is dictated by the severity of the bleed, the current inhibitor titre, the previous anamnestic response to FVIII/IX, the previous clinical response and the side‐effect profile of the agents available. We have reviewed novel dose‐regimens and modes of administration of FEIBA (factor VIII inhibitor bypassing activity) and recombinant activated FVII (rVIIa) and the extent to which these agents may be used for prophylaxis and surgery. Bleeding in acquired haemophilia is usually treated with FEIBA or rVIIa. Immunosuppressive therapy should be initiated at the time of diagnosis with Prednisolone 1 mg/kg/d ± cyclophosphamide. In the absence of a response to these agents within 6 weeks, second‐line therapy with Rituximab, Ciclosporin A, or other multiple‐modality regimens may be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lusher, J. M., Arkin, S., Abildgaard, C. F., & Schwartz, R. S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280701 · Cited by 476
Cited by
International Recommendations on the Diagnosis and Treatment of Acquired Hemophilia A
Tiede, A., Collins, P., Knoebl, P., Teitel, J., Kessler, C., Shima, M., Di Minno, G., d’Oiron, R., Salaj, P., Jiménez-Yuste, V., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.230771 · Cited by 401
Self-citationBaudo, F., Collins, P., Huth-Kühne, A., Lévesque, H., Marco, P., Nemes, L., Pellegrini, F., Tengborn, L., & Knoebl, P. (2012) · Blood · doi:10.1182/blood-2012-02-408930 · Cited by 386
Self-citationInternational workshop on immune tolerance induction: consensus recommendations1
DIMICHELE, D. M., HOOTS, W. K., PIPE, S. W., RIVARD, G. E., & SANTAGOSTINO, E. (2007) · Haemophilia · doi:10.1111/j.1365-2516.2007.01497.x · Cited by 278
Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO
W Collins, P., Chalmers, E., Hart, D., Jennings, I., Liesner, R., Rangarajan, S., Talks, K., Williams, M., & R. M. Hay, C. (2013) · British Journal of Haematology · doi:10.1111/bjh.12463 · Cited by 159
Self-citation
Metadata
- Authors
- Hay, C. R. M., Brown, S., Collins, P. W., Keeling, D. M., & Liesner, R.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2006-05-16
- Volume
- 133
- Issue
- 6
- Pages
- 591-605
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2108177522
- Cited by
- 327
- References
- 1
- FWCI
- 14.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. https://app.cochat.ai/papers/10.1111/j.1365-2141.2006.06087.x
- The paper
- Hay, C. R. M., Brown, S., Collins, P. W., Keeling, D. M., & Liesner, R. (2006). The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2006.06087.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.